U.S., Dec. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07264569) titled 'Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001' on May 19.
Brief Summary: Phase Ib/II clinical study on evaluating the safety, tolerance, biodistribution characteristics and preliminary efficacy of recombinant human nsIL12 oncolytic adenovirus injection (BioTT001) in the treatment of meningeal metastasis in recurrent/progressive non-small cell lung cancer
Study Start Date: June 25
Study Type: INTERVENTIONAL
Condition:
Meningeal Metastasis
Intervention:
BIOLOGICAL: BioTTT001 injection
BioTTT001 is administered as a Intrathecal injection using an Ommaya reservoir.The dosa...